These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 35038851)

  • 1. [Using Lurasidone in the treatment of mental illness in childhood].
    Goryunov AV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(11. Vyp. 2):77-85. PubMed ID: 35038851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lurasidone: The 2016 update on the pharmacology, efficacy and safety profile.
    Jaeschke RR; Sowa-Kućma M; Pańczyszyn-Trzewik P; Misztak P; Styczeń K; Datka W
    Pharmacol Rep; 2016 Aug; 68(4):748-55. PubMed ID: 27203278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders.
    Pompili M; Verzura C; Trovini G; Buscajoni A; Falcone G; Naim S; Nardella A; Sorice S; Baldessarini RJ; Girardi P
    Expert Opin Drug Saf; 2018 Feb; 17(2):197-205. PubMed ID: 28902525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The development of lurasidone for bipolar depression.
    Loebel A; Xu J; Hsu J; Cucchiaro J; Pikalov A
    Ann N Y Acad Sci; 2015 Nov; 1358():95-104. PubMed ID: 26771990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lurasidone in Children and Adolescents: Systematic Review and Case Report.
    Channing J; Mitchell M; Cortese S
    J Child Adolesc Psychopharmacol; 2018 Sep; 28(7):428-436. PubMed ID: 30004236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lurasidone: an antipsychotic with antidepressant effects in bipolar depression?
    Keks NA; Hope J; Castle D
    Australas Psychiatry; 2016 Jun; 24(3):289-91. PubMed ID: 27036122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Analysis of Lurasidone in Patients with Schizophrenia and Bipolar Depression.
    Modugula H; Kumar A
    CNS Neurol Disord Drug Targets; 2020; 19(2):109-114. PubMed ID: 32124704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term efficacy and safety of lurasidone in the treatment of schizophrenia].
    Samalin L; Honciuc M; Llorca PM
    Encephale; 2015 Dec; 41(6):541-9. PubMed ID: 26603973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating lurasidone as a treatment option for bipolar disorder.
    Ali Z; Tegin C; El-Mallakh RS
    Expert Opin Pharmacother; 2020 Feb; 21(3):253-260. PubMed ID: 31957501
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders.
    Findling RL; Goldman R; Chiu YY; Silva R; Jin F; Pikalov A; Loebel A
    Clin Ther; 2015 Dec; 37(12):2788-97. PubMed ID: 26631428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lurasidone in the treatment of schizophrenia: a critical evaluation.
    Bruijnzeel D; Yazdanpanah M; Suryadevara U; Tandon R
    Expert Opin Pharmacother; 2015; 16(10):1559-65. PubMed ID: 26111577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features:
    Singh MK; Pikalov A; Siu C; Tocco M; Loebel A
    J Child Adolesc Psychopharmacol; 2020 Dec; 30(10):590-598. PubMed ID: 32392455
    [No Abstract]   [Full Text] [Related]  

  • 15. Longer-Term Effectiveness and Tolerability of Adjunctive Open Lurasidone in Patients With Bipolar Disorder.
    Miller S; Do D; Gershon A; Wang PW; Hooshmand F; Chang LS; Ketter TA
    J Clin Psychopharmacol; 2018 Jun; 38(3):207-211. PubMed ID: 29620693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.
    Tohen M; Ng-Mak D; Rajagopalan K; Halpern R; Chuang CC; Loebel A
    Prim Care Companion CNS Disord; 2017 Jun; 19(3):. PubMed ID: 28590601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.
    Citrome L; Weiden PJ; McEvoy JP; Correll CU; Cucchiaro J; Hsu J; Loebel A
    CNS Spectr; 2014 Aug; 19(4):330-9. PubMed ID: 24330868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression.
    DelBello MP; Tocco M; Pikalov A; Deng L; Goldman R
    J Child Adolesc Psychopharmacol; 2021 Sep; 31(7):494-503. PubMed ID: 34324397
    [No Abstract]   [Full Text] [Related]  

  • 19. Lurasidone for the treatment of irritability and anger in autism spectrum disorders.
    McClellan L; Dominick KC; Pedapati EV; Wink LK; Erickson CA
    Expert Opin Investig Drugs; 2017 Aug; 26(8):985-989. PubMed ID: 28685626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Lurasidone in Children and Adolescents With Bipolar I Depression: A Double-Blind, Placebo-Controlled Study.
    DelBello MP; Goldman R; Phillips D; Deng L; Cucchiaro J; Loebel A
    J Am Acad Child Adolesc Psychiatry; 2017 Dec; 56(12):1015-1025. PubMed ID: 29173735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.